Only one clinical study showed elevated GFAP levels as an indicator of disrupted sleep and sleep‐related disorders in individuals at risk for AD—in particular, for APOE ε4 carriers with sleep disorder who had the highest plasma GFAP compared to non-carriers with or without sleep disorder [260]. This evidence concerns the gene GFAP and Alzheimer disease.